PrimeRFP SCOUT · Federal Contract Recompete Brief

HT001426FE014BPA CALL ORDER for radioactive pharmaceuticals — Sofie Co

Sofie Co holds $30.8M across 107 federal awards, concentrated at Department of Veterans Affairs (VA). This PIID sits alongside 5 related awards under parent HT001424A0002. The prior award was single-bid — competitive dynamics may favor a challenge. Set-aside status: NONE. Recompete timing centers on the Jan 14, 2027 PoP end — agencies typically plan 12–18 months ahead.

Defense Health Agency

Awarding office

Sofie Co

Recipient

Jan 14, 2027

PoP end

$250K

Obligated

$250K

Potential

325412

NAICS

6505

PSC

NONE

Set-aside

1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Sofie Co — $90

Contract facts

NONE

Contract numberHT001426FE014

Also listed asHT001424A0002-HT001426FE014

AgencyDefense Health Agency

Awarding officeDefense Health Agency

Awarding agencyDepartment of Defense (DOD)

Funding agencyDepartment of Defense (DOD)

IncumbentSofie Co

CAGE09QR8

UEIJV1AHJHGUGG3

NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505

Parent IDIQ / IDVHT001424A0002

Place of performanceBETHESDA MD

Pricing typeFirm Fixed Price

Extent competedNot Competed Under SAP

PoP startJan 15, 2026

PoP end (current)Jan 14, 2027

Obligated$250K

Current value$250K

Potential value$250K

BPA CALL ORDER FOR RADIOACTIVE PHARMACEUTICALS REQUIRED FOR POSITRON EMISSION TOMOGRAPHY (PET). is a federal NONE award for Defense Health Agency held by Sofie Co. Estimated value $250K ($250K obligated). Current period of performance ends Jan 14, 2027. Last award drew 1 bidder. Place of performance: BETHESDA MD.

BPA CALL ORDER FOR RADIOACTIVE PHARMACEUTICALS REQUIRED FOR POSITRON EMISSION TOMOGRAPHY (PET).

Recompete timing

Public

● Expiring in 146 days

Current PoP ends Jan 14, 2027 (146 days remaining). Agencies typically plan 12–18 months ahead — at 4.8 months out, that window is already open. The buying decision is likely already in motion.

Incumbent footprint

Public record

Sofie Co — $30.8M obligated across 107 awards (firm-wide, all agencies) · lead buyer Department of Veterans Affairs (VA).

% of firm-wide obligated ($30.8M) · all agencies

Department of Veterans Affairs (VA)$27.8M · 90%Department of Defense (DOD)$2.9M · 9%

Open full company profile →

Related awards

Same parent · incumbent

36C25525N0412

F18 PROSTATE-SPECIFIC MEMBRANE AGENT (PSMA) - OPTION YEAR 3

$217K

Aug 31, 2026

36C25026N0023

EXERCISING THE ORDERING PERIOD 5

$2.0M

Sep 30, 2026

36C25025F0011

ORDERING PERIOD 4 FOR OY25

$1.6M

Sep 30, 2026

36C25625N0859

PYLARIFY PIFLUFOLASTAT F18

$1.2M

Sep 30, 2026

36C25023N0051

TO EXERCISE ORDERING PERIOD 2. THE ADDITION OF CU 64 DOSES TO RADIOPHARM PET RX

$872K

Sep 30, 2026

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract HT001426FE014?

HT001426FE014 (BPA CALL ORDER for radioactive pharmaceuticals) is a Defense Health Agency award with a potential value of $250K, currently held by Sofie Co. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded HT001426FE014?

Defense Health Agency awarded HT001426FE014 to Sofie Co (potential $250K).

Who is the incumbent on HT001426FE014?

Sofie Co is the incumbent with $30.8M across 107 related awards in SCOUT’s public footprint. The current period of performance ends Jan 14, 2027.

When does Sofie Co’s HT001426FE014 come up for recompete?

SCOUT tracks a period-of-performance end of Jan 14, 2027. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Jun 24, 2026 · refreshed monthlyLatest procurement action Jan 7, 2026